Vitamin K2 Therapy for Postmenopausal Osteoporosis
AbstractVitamin K may play an important role in the prevention of fractures in postmenopausal women with osteoporosis. Menatetrenone is the brand name of a synthetic vitamin K2 that is chemically identical to menaquinone-4. The present review study aimed to clarify the effect of menatetrenone on the skeleton in postmenopausal women with osteoporosis, by reviewing the results of randomized controlled trials (RCTs) in the literature. RCTs that investigated the effect of menatetrenone on bone mineral density (BMD), measured by dual-energy X-ray absorptiometry and fracture incidence in postmenopausal women with osteoporosis, were identified by a PubMed search for literature published in English. Eight studies met the criteria for RCTs. Small RCTs showed that menatetrenone monotherapy decreased serum undercarboxylated osteocalcin (ucOC) concentrations, modestly increased lumbar spine BMD, and reduced the incidence of fractures (mainly vertebral fracture), and that combined alendronate and menatetrenone therapy enhanced the decrease in serum ucOC concentrations and further increased femoral neck BMD. This review of the literature revealed positive evidence for the effects of menatetrenone monotherapy on fracture incidence in postmenopausal women with osteoporosis. Further studies are required to clarify the efficacy of menatetrenone in combination with bisphosphonates against fractures in postmenopausal women with osteoporosis. View Full-Text
Share & Cite This Article
Iwamoto, J. Vitamin K2 Therapy for Postmenopausal Osteoporosis. Nutrients 2014, 6, 1971-1980.
Iwamoto J. Vitamin K2 Therapy for Postmenopausal Osteoporosis. Nutrients. 2014; 6(5):1971-1980.Chicago/Turabian Style
Iwamoto, Jun. 2014. "Vitamin K2 Therapy for Postmenopausal Osteoporosis." Nutrients 6, no. 5: 1971-1980.